Oliver Schmetzer

Oliver Schmetzer

Auto-generated profile, based on publicly available information

Oliver Schmetzer

Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2017 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
PKPavel Kolkhir
Pavel Kolkhir
MCMartin K. Church
Martin K. Church
KWKarsten Weller
Karsten Weller
MMMartin Metz
Martin Metz
OSOliver Schmetzer
Oliver Schmetzer
MMMarcus Maurer
Marcus Maurer

1 September 2018 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
OSOliver Schmetzer
Oliver Schmetzer
ELElisa Lakin
Elisa Lakin
FTFatih A. Topal
Fatih A. Topal
PPPatricia Preusse
Patricia Preusse
DFDenise Freier
Denise Freier
MMMarcus Maurer
Marcus Maurer

9 April 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MMMarcus Maurer
Marcus Maurer
SASabine Altrichter
Sabine Altrichter
OSOliver Schmetzer
Oliver Schmetzer
JSJörg Scheffel
Jörg Scheffel
MCMartin K. Church
Martin K. Church
MMMartin Metz
Martin Metz
The study of autoimmunity mediated by immunoglobulin E (IgE) autoantibodies, which may be termed autoallergy, is in its infancy. It is now recognized that systemic lupus erythematosus, bullous pemphigoid (BP), and chronic urticaria, both spontaneous and inducible, are most likely to be mediated, at least in part, by IgE autoantibodies. The situation in other conditions, such as autoimmune uveitis, rheumatoid arthritis, hyperthyroid Graves’ disease, autoimmune pancreatitis, and even asthma, is far less clear but evidence for autoallergy is accumulating. To be certain of an autoallergic mechanism, it is necessary to identify both IgE autoantibodies and their targets as has been done with the transmembrane protein BP180 and the intracellular protein BP230 in BP and IL-24 in chronic spontaneous urticaria. Also, IgE-targeted therapies, such as anti-IgE, must have been shown to be of benefit to patients as has been done with both of these conditions. This comprehensive review of the literature on IgE-mediated autoallergy focuses on three related questions. What do we know about the prevalence of IgE autoantibodies and their targets in different diseases? What do we know about the relevance of IgE autoantibodies in different diseases? What do we know about the cellular and molecular effects of IgE autoantibodies? In addition to providing answers to these questions, based on a broad review of the literature, we outline the current gaps of knowledge in our understanding of IgE autoantibodies and describe approaches to address them.

5 September 2012
Verified
Book Chapter
Closed access
PDF file
OSOliver Schmetzer
Oliver Schmetzer
AFAnne Flörcken
Anne Flörcken

1 November 2014 in Journal of Immunological Methods
Verified
Journal Article
Closed access
OSOliver Schmetzer
Oliver Schmetzer
PVPatricia Valentin
Patricia Valentin
ASAnna Smorodchenko
Anna Smorodchenko
RDRossana Domenis
Rossana Domenis
GGGiorgia Gri
Giorgia Gri
MMMarcus Maurer
Marcus Maurer

1 April 2006 in Journal of Molecular Biology
Verified
Journal Article
Closed access
DSDidier Salmon
Didier Salmon
RARodolpho do Aido-Machado
Rodolpho do Aido-Machado
ADAnne Diehl
Anne Diehl
MLMartina Leidert
Martina Leidert
OSOliver Schmetzer
Oliver Schmetzer
JPJosé R. Pires
José R. Pires